Title |
Grant Type
Sort ascending
|
Focus Area |
Country |
Application Due Date |
---|---|---|---|---|
The Value of Standardized Diagnosis and Treatment in Patients with Moderate-to-Severe Atopic Dermatitis
Release Date:
|
Research | Inflammation & Immunology | China | |
Real World Evidence of Abrocitinib in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis
Release Date:
|
Research | Inflammation & Immunology | China | |
Junior Investigator Global ATTR Cardiac Amyloidosis Research
Release Date:
|
Research | Rare Disease | Australia, Canada, France, Germany, Italy, Japan, Korea, Spain | |
Cancer Registry
Release Date:
|
Research | Oncology | Congo, The Democratic Republic | |
Quality Improvement Grants to Improve Identification and Management of Patients with ATTR Amyloidosis
Release Date:
|
Quality Improvement | Rare Disease | Spain | |
Quality Improvement Grants to Support Development of Cardiac Amyloid Centers
Release Date:
|
Quality Improvement | Rare Disease | USA | |
Quality Improvement Grants to improve the early suspicion, identification, and the management of patients with ATTR-CM
Release Date:
|
Quality Improvement | Rare Disease | Canada | |
Optimizing maternal immunization practice and vaccination access during pregnancy in Italy
Release Date:
|
Quality Improvement | Vaccines | Italy | |
Enhancing Molecular Testing for Metastatic Colorectal Cancer Patients
Release Date:
Partner: Colorectal Cancer Canada (CCC)
|
Quality Improvement | Oncology | Canada | |
2024 Raising Awareness and Promoting Timely Diagnosis of TTR Amyloidosis
Release Date:
Partner: Global Bridges at Mayo Clinic
|
Quality Improvement | Rare Disease | All | |
Closing the HRRm Testing Gap in Prostate Cancer Patients
Release Date:
|
Quality Improvement | Oncology | Canada |
Title |
Grant Type
Sort ascending
|
Focus Area |
Country |
Application Due Date |
---|---|---|---|---|
Investigating the Value of Using Patient-Reported Outcomes in Oncology Patient Care
|
Research | Oncology | USA | |
Real World Evidence of Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis
Release Date:
|
Research | Inflammation & Immunology | All | |
2023/2024 Global NASH ASPIRE
Release Date:
|
Research | Internal Medicine | All | |
Diversity in Postmarketing Drug Safety Surveillance
Release Date:
|
Research | Patient Safety | USA | |
Improving Health Equity in IBD through Disparities Research
Release Date:
|
Research | Inflammation & Immunology | All | |
Burden of RSV Disease - Analyzing Local Surveillance Data for Older Adults (EM Geographic Scope)
Release Date:
|
Research | Inflammation & Immunology | All | |
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Research in Canada
Release Date:
|
Research | Rare Disease | Canada | |
Quantifying the Socio-Economic Burden of Disease for Dermatology Patients and Caregivers
Release Date:
|
Research | Inflammation & Immunology | Australia, Austria, Belgium, Canada, Czech Republic, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Japan, Luxembourg, Netherlands, Norway, Poland, Portugal, Romania, Slovakia (Slovak Republic), Spain, Sweden, Switzerland, United Kingdom | |
Ulcerative Colitis (UC) Research
Release Date:
|
Research | Inflammation & Immunology | Albania, Andorra, Australia, Austria, Belarus, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Holy See (Vatican City State), Hungary, Iceland, Ireland, Israel, Italy, Korea, Latvia, Liechtenstein, Lithuania, Luxembourg, Macedonia, The Former Yugoslav, Malta, Moldova, Republic of, Monaco, Netherlands, New Zealand, Norway, Poland, Portugal, Romania, San Marino, Slovakia (Slovak Republic), Slovenia, Spain, Sweden, Switzerland, Ukraine, United Kingdom | |
Novel Digital Diagnostic Approaches in Acromegaly and Sickle Cell Disease
Release Date:
|
Research | Rare Disease | USA | |
Alopecia Areata (Global)
Release Date:
|
Research | Inflammation & Immunology | USA | |
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Research in Canada
Release Date:
|
Research | Rare Disease | Canada |